Insider Selling: DermTech, Inc. (NASDAQ:DMTK) COO Sells $14,239.54 in Stock

DermTech, Inc. (NASDAQ:DMTK) COO Claudia Ibarra sold 7,378 shares of the stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $1.93, for a total value of $14,239.54. Following the completion of the transaction, the chief operating officer now directly owns 200,718 shares in the company, valued at approximately $387,385.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Claudia Ibarra also recently made the following trade(s):

• On Monday, September 11th, Claudia Ibarra sold 322 shares of DermTech stock. The stock was sold at an average price of $1.89, for a total value of $608.58.

DermTech Stock Performance

NASDAQ DMTK opened at $1.94 on Friday. The stock’s 50 day moving average price is $2.68 and its two-hundred day moving average price is $3.00. DermTech, Inc. has a 52 week low of $1.55 and a 52 week high of $6.44.

DermTech (NASDAQ:DMTK) last posted its quarterly earnings results on Thursday, August 3rd. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.95) by ($0.04). The company had revenue of $3.98 million for the quarter, compared to analyst estimates of $3.55 million. DermTech had a negative return on equity of 99.14% and a negative net margin of 853.02%. Analysts anticipate that DermTech, Inc. will post -3.56 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in DMTK. XTX Topco Ltd acquired a new position in shares of DermTech during the 2nd quarter worth approximately $33,000. Advisor Group Holdings Inc. grew its holdings in DermTech by 251.8% in the 4th quarter. Advisor Group Holdings Inc. now owns 20,090 shares of the company’s stock valued at $36,000 after buying an additional 14,380 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in DermTech in the 4th quarter valued at $38,000. Charles Schwab Investment Management Inc. acquired a new position in DermTech in the 1st quarter valued at $42,000. Finally, Kovack Advisors Inc. acquired a new position in DermTech in the 1st quarter valued at $43,000. Institutional investors and hedge funds own 27.81% of the company’s stock.

Analysts Set New Price Targets

Separately, BTIG Research dropped their price target on DermTech from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, August 7th.

About DermTech

DermTech, Inc, a molecular diagnostic company, develops and markets novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer and inflammatory diseases in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers.